|
1
|
Lloyd-Jones DM, Larson MG, Leip EP, Beiser
A, D'Agostino RB, Kannel WB, Murabito JM, Vasan RS, Benjamin EJ and
Levy D: Framingham Heart Study: Lifetime risk for developing
congestive heart failure-The Framingham Heart Study. Circulation.
106:3068–3072. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lloyd-Jones DM, Wang TJ, Leip EP, Larson
MG, Levy D, Vasan RS, D'Agostino RB, Massaro JM, Beiser A, Wolf PA
and Benjamin EJ: Lifetime risk for development of atrial
fibrillation - The Framingham Heart Study. Circulation.
110:1042–1046. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Anselmino M, Matta M and Gaita F: Catheter
ablation of atrial fibrillation in patients with heart failure: Can
we break the vicious circle? Eur J Heart Fail. 17:1003–1005. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cooper HA, Bloomfield DA, Bush DE, Katcher
MS, Rawlins M, Sacco JD and Chandler M: AFFIRM Investigators:
Relation between achieved heart rate and outcomes in patients with
atrial fibrillation (from the Atrial Fibrillation Follow-up
Investigation of Rhythm Management [AFFIRM] Study). Am J Cardiol.
93:1247–1253. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
January CT, Wann LS, Alpert JS, Calkins H,
Cigarroa JE, Cleveland JC Jr, Conti JB, Ellinor PT, Ezekowitz MD,
Field ME, et al: ACC/AHA Task Force Members: 2014 AHA/ACC/HRS
guideline for the management of patients with atrial fibrillation:
Executive summary: A report of the American College of
Cardiology/American Heart Association Task Force on practice
guidelines and the Heart Rhythm Society. Circulation.
130:2071–2104. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Anselmino M, Matta M, D'Ascenzo F, Bunch
TJ, Schilling RJ, Hunter RJ, Pappone C, Neumann T, Noelker G, Fiala
M, et al: Catheter ablation of atrial fibrillation in patients with
left ventricular systolic dysfunction: A systematic review and
meta-analysis. Circ Arrhythm Electrophysiol. 7:1011–1018. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Young-Xu Y, Jabbour S, Goldberg R, Blatt
CM, Graboys T, Bilchik B and Ravid S: Usefulness of statin drugs in
protecting against atrial fibrillation in patients with coronary
artery disease. Am J Cardiol. 92:1379–1383. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Horwich TB, MacLellan WR and Fonarow GC:
Statin therapy is associated with improved survival in ischemic and
non-ischemic heart failure. J Am Coll Cardiol. 43:642–648. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Maggioni AP, Fabbri G, Lucci D, Marchioli
R, Franzosi MG, Latini R, Nicolosi GL, Porcu M, Cosmi F, Stefanelli
S, et al: GISSI-HF Investigators: Effects of rosuvastatin on atrial
fibrillation occurrence: Ancillary results of the GISSI-HF trial.
Eur Heart J. 30:2327–2336. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Xia W, Yin Z, Li J, Song Y and Qu X:
Effects of rosuvastatin on asymmetric dimethylarginine levels and
early atrial fibrillation recurrence after electrical
cardioversion. Pacing Clin Electrophysiol. 32:1562–1566. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yancy CW, Jessup M, Bozkurt B, Butler J,
Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi
JL, et al: American College of Cardiology Foundation; American
Heart Association Task Force on Practice Guidelines: 2013 ACCF/AHA
guideline for the management of heart failure: A report of the
American College of Cardiology Foundation/American Heart
Association Task Force on Practice Guidelines. J Am Coll Cardiol.
62:e147–e239. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hunt SA, Abraham WT, Chin MH, Feldman AM,
Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K,
et al: American College of Cardiology, American Heart Association
Task Force on Practice Guidelines, American College of Chest
Physicians, International Society for Heart and Lung
Transplantation, Heart Rhythm Society: ACC/AHA 2005 Guideline
Update for the Diagnosis and Management of Chronic Heart Failure in
the Adult: A report of the American College of Cardiology/American
Heart Association Task Force on Practice Guidelines (Writing
Committee to Update the 2001 Guidelines for the Evaluation and
Management of Heart Failure): Developed in collaboration with the
American College of Chest Physicians and the International Society
for Heart and Lung Transplantation: Endorsed by the Heart Rhythm
Society. Circulation. 112:e154–e235. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ponikowski P, Voors AA, Anker SD, Bueno H,
Cleland JG, Coats AJ, et al: ESC Guidelines for the Diagnosis and
Treatment of Acute and Chronic Heart Failure. Rev Esp Cardiol.
69:11672016.PubMed/NCBI
|
|
14
|
Imai E, Horio M, Nitta K, Yamagata K,
Iseki K, Tsukamoto Y, Ito S, Makino H, Hishida A and Matsuo S:
Modification of the modification of diet in Renal Disease (MDRD)
study equation for Japan. Am J Kidney Dis. 50:927–937. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hunter RJ, Berriman TJ, Diab I, Kamdar R,
Richmond L, Baker V, Goromonzi F, Sawhney V, Duncan E, Page SP, et
al: A randomized controlled trial of catheter ablation versus
medical treatment of atrial fibrillation in heart failure (the
CAMTAF trial). Circ Arrhythm Electrophysiol. 7:31–38. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Thihalolipavan S and Morin DP: Atrial
fibrillation and heart failure: Update 2015. Prog Cardiovasc Dis.
58:126–135. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Machino-Ohtsuka T, Seo Y, Ishizu T, Sugano
A, Atsumi A, Yamamoto M, Kawamura R, Machino T, Kuroki K, Yamasaki
H, et al: Efficacy, safety, and outcomes of catheter ablation of
atrial fibrillation in patients with heart failure with preserved
ejection fraction. J Am Coll Cardiol. 62:1857–1865. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Maron DJ, Fazio S and Linton MF: Current
perspectives on statins. Circulation. 101:207–213. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liao JK and Laufs U: Pleiotropic effects
of statins. Annu Rev Pharmacol Toxicol. 45:89–118. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kim YM, Guzik TJ, Zhang YH, Zhang MH,
Kattach H, Ratnatunga C, Pillai R, Channon KM and Casadei B: A
myocardial Nox2 containing NAD(P)H oxidase contributes to oxidative
stress in human atrial fibrillation. Circ Res. 97:629–636. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Reilly SN, Jayaram R, Nahar K, Antoniades
C, Verheule S, Channon KM, Alp NJ, Schotten U and Casadei B: Atrial
sources of reactive oxygen species vary with the duration and
substrate of atrial fibrillation: Implications for the
antiarrhythmic effect of statins. Circulation. 124:1107–1117. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Recalde A, Carnicer R, Simon J, Reilly S,
Verheule S, Shah AM, et al: Increased atrial fibrillation
susceptibility in mice with myocardial specific NOX2 overexpression
is prevented by short term statin treatment. Eur Heart J.
35:11182014.
|
|
23
|
Peña JM, MacFadyen J, Glynn RJ and Ridker
PM: High-sensitivity C-reactive protein, statin therapy, and risks
of atrial fibrillation: An exploratory analysis of the JUPITER
trial. Eur Heart J. 33:531–537. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Walfridsson H, Walfridsson U, Nielsen JC,
Johannessen A, Raatikainen P, Janzon M, Levin LA, Aronsson M,
Hindricks G, Kongstad O, et al: Radiofrequency ablation as initial
therapy in paroxysmal atrial fibrillation: Results on
health-related quality of life and symptom burden. The MANTRA-PAF
trial. Europace. 17:215–221. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Morillo CA, Verma A, Connolly SJ, Kuck KH,
Nair GM, Champagne J, Sterns LD, Beresh H, Healey JS and Natale A:
RAAFT-2 investigators: Radiofrequency ablation vs antiarrhythmic
drugs as first-line treatment of paroxysmal atrial fibrillation
(RAAFT-2): A randomized trial. JAMA. 311:692–700. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Rillig A, Makimoto H, Wegner J, Lin T,
Heeger C, Lemes C, Fink T, Metzner A, Wissner E, Mathew S, et al:
Six-year clinical outcomes after catheter ablation of atrial
fibrillation in patients with impaired left ventricular function. J
Cardiovasc Electrophysiol. 26:1169–1179. 2015. View Article : Google Scholar
|
|
27
|
Takagi H and Umemoto T: Atorvastatin, not
rosuvastatin, improves cardiac function in heart failure: A
meta-analysis of randomized trials. Int J Cardiol. 155:296–299.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Loricchio ML, Cianfrocca C, Pasceri V,
Bianconi L, Auriti A, Calo L, Lamberti F, Castro A, Pandozi C,
Palamara A, et al: Relation of C-reactive protein to long-term risk
of recurrence of atrial fibrillation after electrical
cardioversion. Am J Cardiol. 99:1421–1424. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Schiffrin EL: The immune system: Role in
hypertension. Can J Cardiol. 29:543–548. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Xu J, Cui G, Esmailian F, Plunkett M,
Marelli D, Ardehali A, Odim J, Laks H and Sen L: Atrial
extracellular matrix remodeling and the maintenance of atrial
fibrillation. Circulation. 109:363–368. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Jalife J and Kaur K: Atrial remodeling,
fibrosis, and atrial fibrillation. Trends Cardiovasc Med.
25:475–484. 2015. View Article : Google Scholar : PubMed/NCBI
|
